Satellos Bioscience Inc. Announces First Quarter Financial Results and Operational Highlights
Toronto, Ontario--(Newsfile Corp. - May 31, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutic drugs that change the way degenerative muscle diseases are treated, today announced its unaudited financial results and operational highlights for the quarter ended March 31, 2022 ("Q1 2022"). All dollar amounts in this press release are in Canadian dollars unless otherwise noted."The early months of 2022 has...
2022-05-31 7:00 AM EDT
Satellos Bioscience Announces 2021 Year End Financial Results and Operational Highlights
Toronto, Ontario--(Newsfile Corp. - April 29, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the year ending December 31, 2021. All dollar amounts are expressed in Canadian currency unless otherwise noted."2021 was a transformative year for Satellos, as we continue to...
2022-04-29 7:30 PM EDT
Satellos Bioscience Inc. Invited to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario--(Newsfile Corp. - April 26, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Satellos Bioscience was invited to present at the 2022 Bloom Burton & Co. Healthcare Investor Conference. The conference brings together U.S., Canadian, and international investors interested in the latest...
2022-04-26 7:00 AM EDT
Satellos Bioscience Inc. to Present Game Changing Science at Upcoming European Molecular Biology Organization Workshop
Toronto, Ontario--(Newsfile Corp. - April 21, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Ryan Mitchell, PhD and Director of Business Development will be presenting a poster on Satellos' game changing science during an upcoming European Molecular Biology Organization (EMBO) workshop on muscle formation,...
2022-04-21 7:00 AM EDT
Satellos Bioscience Inc.'s CSO to Present Game Changing Science During March 30th Drug Discovery News Webinar
Toronto, Ontario--(Newsfile Corp. - March 29, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"), a biotechnology company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Michael Rudnicki, PhD, Senior Scientist and Director of the Regenerative Medicine Program and Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute will be presenting at an upcoming Drug Discovery News webinar on stem...
2022-03-29 7:00 AM EDT
Satellos Bioscience Provides Update on Novel Regenerative Drug Candidates
Toronto, Ontario--(Newsfile Corp. - March 15, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a biotechnology company developing therapeutics that have the potential to transform the way degenerative muscle diseases are treated, today announced progress in designing and developing the world's first small molecule drug candidates intended to restore the body's innate cycle of muscle regeneration. Satellos has discovered that muscle degeneration and loss of function...
2022-03-15 7:00 AM EDT
Satellos Bioscience Provides Update on Joint Development Initiative with NW PharmaTech Limited
Toronto, Ontario--(Newsfile Corp. - March 11, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a biotechnology company developing therapeutics that have the potential to transform the way degenerative muscle diseases are treated, today announced progress towards monetizing its novel and proprietary oral pharmaceutical transport technology ("OralTransTM").Satellos and NW PharmaTech Limited ("NW PharmaTech") are pleased to announce further developments in their joint...
2022-03-11 7:00 AM EST
Satellos Bioscience Inc. to Present Game Changing Science at Insights in Research Investor Summit and MDA Clinical & Scientific Conference 2022
Toronto, Ontario--(Newsfile Corp. - March 10, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Satellos has been selected to present at the upcoming Insights in Research Investor Summit and MDA Clinical and Scientific Conference Nashville, Tennessee, March 13-16, 2022. Dr. Ryan Mitchell, Director of Business...
2022-03-10 7:00 AM EST
Satellos Bioscience to Participate at BIO CEO & Investor Conference 2022
Toronto, Ontario--(Newsfile Corp. - February 10, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that Frank Gleeson, President and CEO, will present at the BIO CEO & Investor Conference being held in New York, NY and virtually. In addition to the presentation, management will be available to participate in virtual...
2022-02-10 7:00 AM EST
Satellos Bioscience Inc. Announces CEO Letter to Shareholders
Toronto, Ontario--(Newsfile Corp. - January 24, 2022) - Satellos Bioscience Inc. (TSXV: MSCL)To our shareholders,Satellos Bioscience Inc. (TSXV: MSCL) (OTC: MSCLF) ("Satellos") is at the forefront of bold new science. Our research team has made seminal and, to many, game changing discoveries into the body's regenerative processes. Based on these discoveries, Satellos is in the process of developing an entirely novel category of medicines - drug products that are expected to reset the body's...
2022-01-24 7:00 AM EST
Satellos Bioscience to Participate at Biotech Showcase(TM) Virtual 2022
Toronto, Ontario--(Newsfile Corp. - January 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that Frank Gleeson, President and CEO, will present virtually at the Biotech Showcase™ 2022 conference and conduct virtual one-on-one meetings with investors during the conference.Presentation Date: January 10, 2022Registration:...
2022-01-06 7:00 AM EST
Satellos Bioscience Inc. Announces Scientific Research Agreement with Université de Sherbrooke to Study Rare Muscular Dystrophies
Toronto, Ontario--(Newsfile Corp. - December 16, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation") is pleased to announce that it has entered into a scientific research agreement (the "Agreement") with Université de Sherbrooke. ("UdeS"). Under the Agreement, Satellos and UdeS will collaborate on research activities to identify additional disease indications for Satellos' novel muscle regeneration technology in selected preclinical models of rare muscular...
2021-12-16 7:00 AM EST
Satellos Bioscience Announces New Board Appointments
Satellos welcomes new board members to strengthen its pharmaceutical and North American capital markets expertise in support of its value-build strategyToronto, Ontario--(Newsfile Corp. - December 6, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today the appointment of Dr. Rima Al-awar, PhD and Mr. Adam Mostafa to its board of...
2021-12-06 7:00 AM EST
Satellos Bioscience Reports Third Quarter 2021 Financial Results and Operational Highlights
Satellos positioned to pursue the development of first-in-class regenerative therapeutic treatments for degenerative muscle diseases.Toronto, Ontario--(Newsfile Corp. - November 29, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company, formerly known as iCo Therapeutics Inc. ("iCo"), aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational...
2021-11-29 12:51 PM EST
Satellos Bioscience Inc. Retains BND Projects Inc. for Strategic Investor Relations Services
Toronto, Ontario--(Newsfile Corp. - October 27, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation") is pleased to announce that it has entered into an investor relations agreement (the "Investor Relations Agreement") with BND Projects Inc. ("BND") whereby BND will provide strategic investor relations services. BND will aid the Corporation in building awareness in the financial community by introducing, maintaining and protecting relationships between the management...
2021-10-27 7:00 AM EDT
Satellos Bioscience Announces Appointment of J. Robert Hall as Vice-President, Finance and Administration
Toronto, Ontario--(Newsfile Corp. - September 17, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) (Satellos" or the "Company"), a regenerative medicine company focused on the treatment of Duchenne muscular dystrophy and other degenerative or muscle wasting disorders, is pleased to announce that the Company's board of directors has appointed J. Robert Hall, CFA as Vice-President, Finance & Administration.Mr. Hall has been with Satellos since January of 2020, serving in various finance and...
2021-09-17 8:00 AM EDT
Satellos Bioscience Announces Evidence for Regeneration in Severe Model of Duchenne
Toronto, Ontario--(Newsfile Corp. - September 13, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"), a regenerative medicine company focused on the treatment of degenerative muscle disorders, announced today core findings from additional preclinical drug development studies in their lead program to treat Duchenne muscular dystrophy ("Duchenne"). Satellos scientists are developing small molecule drugs with the goal of restoring faulty regeneration and repair observed in the muscles of...
2021-09-13 7:00 AM EDT
Satellos Bioscience Announces Partnership with Jesse's Journey
Toronto, Ontario--(Newsfile Corp. - September 7, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"), and Jesse's Journey, Canada's leader in Duchenne muscular dystrophy funded research, are proud to announce a research partnership and infrastructure grant to support the development of Satellos' novel approach to treating Duchenne.Satellos scientists are developing small molecule drugs that they believe will restore faulty regeneration and repair observed in the muscles of patients...
2021-09-07 7:00 AM EDT
Satellos Bioscience Announces Second Quarter 2021 Financial Results and MD&A
Toronto, Ontario--(Newsfile Corp. - August 30, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos"), formerly iCo Therapeutics Inc. ("iCo"), today filed financial results and MD&A reports for the second quarter which ended on June 30, 2021, on SEDAR. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards.Satellos is developing small molecule drugs that restore faulty regeneration and repair observed in the...
2021-08-30 5:43 PM EDT
Satellos Bioscience Announces High Resolution Crystal Structure of Duchenne Drug Target
Toronto, Ontario--(Newsfile Corp. - August 27, 2021) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos") announced today that they have successfully determined a high resolution (1.85Å) X-ray crystal structure of their novel drug target for Duchenne muscular dystrophy ("Duchenne").Satellos scientists are developing small molecule drugs that restore faulty regeneration and repair observed in the muscles of patients with Duchenne and potentially other degenerative muscle disorders. The...
2021-08-27 7:00 AM EDT